Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.
Your view on INTS
Overview
What the company does, where it operates, and who runs it.
About Intensity Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lewis H. Bender
- Headquarters
- 61 Wilton Road, Westport, CT, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lewis H. Bender
- Headquarters
- 61 Wilton Road, Westport, CT, US
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors.
The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.
It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.
The company was founded in 2012 and is headquartered in Westport, Connecticut.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Intensity Therapeutics, Inc., and the rating behind it. INTS last traded at $4.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Intensity Therapeutics, Inc.. Starting points for Intensity Therapeutics, Inc.: EPS -$0.41, beta 3.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Intensity Therapeutics, Inc.. Intensity Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Intensity Therapeutics, Inc.. Trailing twelve-month EPS for Intensity Therapeutics, Inc. stands at -$0.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Intensity Therapeutics, Inc.. Intensity Therapeutics, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Intensity Therapeutics, Inc. valued side by side against its closest peers. Intensity Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Intensity Therapeutics, Inc., and how their positions are changing. At a $10.9M market value, institutional positions materially move Intensity Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Intensity Therapeutics, Inc. executives and directors. Shares of Intensity Therapeutics, Inc. have traded between $0.18 and $3.18 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Intensity Therapeutics, Inc.. Intensity Therapeutics, Inc. is a $10.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Intensity Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Intensity Therapeutics, Inc.. Coverage tracks Intensity Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.